For the twenty-one million American adults experiencing major depressive disorder (MDD) annually, this FDA-cleared treatment ...

Spruce Biosciences discontinues tildacerfont trials for CAH as CAHmelia-204 misses primary endpoint and CAHptain-205 shows ...

The wish to die is usually transient, or at least time-limited and reversible. Having a support system with an explicit plan ...

Relmada is now scrapping Reliance II, plus another phase 3 trial called Relight, which was assessing REL-1017 as an add-on ...

Relmada Therapeutics said on Wednesday its depression treatment was "unlikely" to meet the main goal of a late-stage trial based on an independent data monitoring committee's analysis, sending the ...

Relmada Therapeutics lost more than two-thirds of its market value early Wednesday after the biotechnology company said a treatment for major depressive disorder would likely fail to meet its primary ...

An actor and stunt coordinator who injured his leg has reached his £25,000 fundraising target for treatment with the help of star and friend Russell Crowe. Charlie Allan, 61, from the Scottish ...

eHarvard T H Chan, School of Public Health, Harvard University, Boston, MA, USA ...

Biohaven said its potential treatment for spinal muscular atrophy had not shown statistically different results from the control on the primary outcome in a clinical study. The New Haven ...

Minimally adequate treatment for major depressive disorders is defined as at least ... Organization's Comprehensive Mental Health Action Plan 2013–2030, which aims to increase mental health ...

1 Departamento de Nutrición y Bioquímica, Pontificia Universidad Javeriana, Bogotá, Colombia 2 Instituto de Genética Humana, Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, Colombia ...